199 related articles for article (PubMed ID: 34298614)
21. The Expression and Clinical Significance of Aldo-Keto Reductase 1 Member B1 in Gastric Carcinoma.
Li X; Yang J; Gu X; Xu J; Li H; Qian J; Chen L
DNA Cell Biol; 2020 Jul; 39(7):1322-1327. PubMed ID: 32412859
[TBL] [Abstract][Full Text] [Related]
22. Impact of cytotoxic chemotherapy on aldo-keto reductase family 1 member B10 expression.
Robinson K; Cao Z; Delfino K; Cao D; Rao K
J Int Med Res; 2023 Jun; 51(6):3000605231179317. PubMed ID: 37389562
[TBL] [Abstract][Full Text] [Related]
23. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
Liu TA; Jan YJ; Ko BS; Wu YJ; Lu YJ; Liang SM; Liu CC; Chen SC; Wang J; Shyue SK; Liou JY
Oncotarget; 2015 Nov; 6(36):38967-82. PubMed ID: 26516929
[TBL] [Abstract][Full Text] [Related]
24. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liu W; Song J; Du X; Zhou Y; Li Y; Li R; Lyu L; He Y; Hao J; Ben J; Wang W; Shi H; Wang Q
Acta Biomater; 2019 Jun; 91():195-208. PubMed ID: 31034948
[TBL] [Abstract][Full Text] [Related]
25. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
26. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Han C; Gao L; Bai H; Dou X
Oncol Lett; 2018 Dec; 16(6):7123-7130. PubMed ID: 30546447
[TBL] [Abstract][Full Text] [Related]
27. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
28. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Tsuzura H; Genda T; Sato S; Murata A; Kanemitsu Y; Narita Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Ichida T
Int J Mol Sci; 2014 Apr; 15(4):6556-68. PubMed ID: 24747592
[TBL] [Abstract][Full Text] [Related]
29. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Fukumoto S; Yamauchi N; Moriguchi H; Hippo Y; Watanabe A; Shibahara J; Taniguchi H; Ishikawa S; Ito H; Yamamoto S; Iwanari H; Hironaka M; Ishikawa Y; Niki T; Sohara Y; Kodama T; Nishimura M; Fukayama M; Dosaka-Akita H; Aburatani H
Clin Cancer Res; 2005 Mar; 11(5):1776-85. PubMed ID: 15755999
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
[TBL] [Abstract][Full Text] [Related]
32. Cancer biomarker AKR1B10 and carbonyl metabolism.
Balendiran GK; Martin HJ; El-Hawari Y; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):134-7. PubMed ID: 19028477
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
[TBL] [Abstract][Full Text] [Related]
34. Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Ko HH; Cheng SL; Lee JJ; Chen HM; Kuo MY; Cheng SJ
Head Neck; 2017 Jul; 39(7):1327-1332. PubMed ID: 28301069
[TBL] [Abstract][Full Text] [Related]
35. AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Shaw N; Yang B; Millward A; Demaine A; Hodgkinson A
Cell Stress Chaperones; 2014 Mar; 19(2):281-7. PubMed ID: 23975544
[TBL] [Abstract][Full Text] [Related]
36. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
[TBL] [Abstract][Full Text] [Related]
37. Selective Inhibition of Human AKR1B10 by
Seliger JM; Cicek SS; Witt LT; Martin HJ; Maser E; Hintzpeter J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30469331
[TBL] [Abstract][Full Text] [Related]
38. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.
Khayami R; Hashemi SR; Kerachian MA
J Cell Mol Med; 2020 Aug; 24(16):8890-8902. PubMed ID: 32633024
[TBL] [Abstract][Full Text] [Related]
39. Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Guo Y; Luo W; Hu Z; Li J; Li X; Cao H; Li J; Wen B; Zhang J; Cheng H; Guo W; Tan T; Luo D
Cell Biosci; 2016; 6():18. PubMed ID: 26949513
[TBL] [Abstract][Full Text] [Related]
40. AKR1B10, a good prognostic indicator in gastric cancer.
Yao HB; Xu Y; Chen LG; Guan TP; Ma YY; He XJ; Xia YJ; Tao HQ; Shao QS
Eur J Surg Oncol; 2014 Mar; 40(3):318-24. PubMed ID: 24406159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]